DMVF3D1000 VAREJO FARMA PARTICIPAÇÕES S.A.Company Data · 2T26updated 2026-08-24
1
Overview
4T19 — 2T26 · 27 quarters
▼
D1000 VAREJO FARMA PARTICIPAÇÕES S.A.
d1000 Varejo Farma Participações S.A. engages in the retail sale of pharmaceutical and perfumery products in Brazil. It sells generic drugs, OTC, and personal care and beauty products. The company was formerly known as Cancun RJ Participações S/A and changed its name to d1000 Varejo Farma Participações S.A. in March 2016. The company was incorporated in 2010 and is headquartered in Rio De Janeiro, Brazil. d1000 Varejo Farma Participações S.A. is a subsidiary of Profarma Distribuidora de Produtos Farmacêuticos S.A.
SectorComércio (Atacado e Varejo)
Company HeadquartersRio De Janeiro, RJ
Full Time Employees4.500
CEOMr. Sammy Birmarcker
Listing SegmentNovo Mercado
Foundation2010
Customer Rating—
Employee Rating—
Estrutura Acionária
20%Free Float
Profarma Distribuidora De Produtos Farmacêuticos S.A.72%
LIS Capital Gestora Ltda8%
Free Float20%
Valuation
| Price | R$ 6,28 |
| Shares Outstanding | 50.603 |
| Market Capitalization | 318 |
| ( - ) Cash & Equivalents | 26 |
| ( + ) Total Debt | 60 |
| ( = ) Enterprise Value | 351 |
| P/E | 14,6x |
| EV / EBITDA | 1,5x |
R$ 6,28
Adj close · daily
Income Statement
| Revenue | 2.751 |
| EBITDA | 233 |
| EBIT | 90 |
| Net Income | 22 |
| SG&A % | (26,9%) |
Balance Sheet
| Assets | 2.025 |
| Cash | 26 |
| Total Debt | 60 |
| Net Debt | 33 |
| Fixed Assets | 1.214 |
| Working Capital | 132 |
| Equity | 924 |
Invested Capital & Reinvestment
| Invested Capital Turnover | 2,05x |
| Marginal IC Turnover | (0,35x) |
| Reinvestment % NOPAT | 59,4% |
| Working Capital Turnover | 19,38x |
| Cash Conv. Cycle | 15,8 |
| Fixed Assets Turnover | 2,32x |
| D&A % Fixed Assets | 4,4% |
| Capex % Revenue | 3,9% |
7,7 %
RoIC · LTM
RoIC (LTM)
Margins & Returns
| Revenue Growth | 14,1% |
| Gross Margin | 29,6% |
| EBITDA Margin | 8,5% |
| Net Income Margin | 0,8% |
| Effective Tax Rate | (16,3%) |
| Operating Leverage | 2,95x |
| RoIC | 7,7% |
| RoE | 2,4% |
Capital Structure
| Current Ratio | 1,01x |
| Financial Leverage | 2,19x |
| Asset Turnover | 1,40x |
| Net Debt / EBITDA | 0,14x |
| Net Debt & Lease / EBITDA | 1,97x |
Cash Flow
| CFO Conversion | 88,8% |
| FCFF Yield | 27,3% |
| FCFE Yield | 41,5% |
| Payout Ratio | 0,0% |
| Dividend Yield | 0,0% |
| Interest % FCFF | 0,0% |
Latest CVM filings
- 2026-07-29reported 2T26
- 2026-05-06reported 1T26
- 2026-03-16reported 4T25
- 2025-10-29reported 3T25
- 2025-07-30reported 2T25
- 2025-05-05reported 1T25